Cite

HARVARD Citation

    Norris, S. et al. (2017). Evaluation of the immunogenicity of the dabigatran reversal agent idarucizumab during Phase I studies. British journal of clinical pharmacology. pp. 1815-1825. [Online]. 
  
Back to record